AngioDynamics Inc (ANGO)
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
- Symbol
- ANGO
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $646.77M
- 52 week range
- 9.39 - 16.29
Valuation
- Share price
- $15.33 (close of 2026-09-23)
- P/E (TTM)
- -17.63x
- Price to book
- 3.79x
- Price to free cash flow
- 1273.18x
- Enterprise value
- $603.87M
- Book value per share
- $4.10
Price performance
| Period | Change |
|---|
| 1 day | -0.58% |
| 5 days | -2.23% |
| 1 month | -2.67% |
| 3 months | +23.93% |
| 6 months | +43.14% |
| Year to date | +19.39% |
| 1 year | +42.08% |
| 3 years | +118.38% |
| 5 years | -36.94% |
| 10 years | -11.90% |
| All time | +12.72% |
Profitability and growth
- Return on equity
- -21.51%
- Return on invested capital
- -31.21%
- Return on assets
- -13.75%
- Return on capital employed
- -20.75%
- Gross margin
- 54.62%
- Net margin
- -11.48%
- EBITDA margin
- -5.30%
- Revenue growth
- 9.46%
- Net income growth
- -8.09%
- Free cash flow growth
- 103.48%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 0.08%
- Current ratio
- 2.19x
- Net debt to EBITDA
- -68.54x
Latest reported year
- Period end
- 2026-05-31
- Fiscal year
- 2026
- Revenue
- $320.17M
- Cost of revenue
- $145.28M
- Gross profit
- $174.89M
- EBITDA
- $-16.97M
- Net income
- $-36.74M
- Earnings per share
- $-0.88
- Research and development
- $29.45M
- Shares outstanding
- 41.53M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2026-05-31 | $320.17M | $174.89M | $-36.74M | $-0.88 |
| 2025-05-31 | $292.50M | $157.71M | $-33.99M | $-0.83 |
| 2024-05-31 | $303.91M | $154.70M | $-184.35M | $-4.59 |
| 2023-05-31 | $338.75M | $174.25M | $-52.44M | $-1.33 |
| 2022-05-31 | $316.22M | $165.73M | $-26.55M | $-0.68 |
| 2021-05-31 | $291.01M | $156.79M | $-31.55M | $-0.82 |
| 2020-05-31 | $264.16M | $150.27M | $-166.79M | $-4.39 |
| 2019-05-31 | $270.63M | $156.00M | $61.34M | $1.64 |
| 2018-05-31 | $261.65M | $143.86M | $16.34M | $0.44 |
| 2017-05-31 | $269.79M | $143.95M | $5.01M | $0.14 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2026-05-31 | 54.62% | -11.48% | -21.51% | -31.21% |
| 2025-05-31 | 53.92% | -11.62% | -18.58% | -29.09% |
| 2024-05-31 | 50.90% | -60.66% | -89.67% | -137.90% |
| 2023-05-31 | 51.44% | -15.48% | -13.86% | -12.35% |
| 2022-05-31 | 52.41% | -8.40% | -6.25% | -5.84% |
| 2021-05-31 | 53.88% | -10.84% | -7.18% | -7.67% |
| 2020-05-31 | 56.89% | -63.14% | -36.67% | -40.34% |
| 2019-05-31 | 57.64% | 22.67% | 9.98% | -1.13% |
| 2018-05-31 | 54.98% | 6.24% | 3.01% | -1.26% |
| 2017-05-31 | 53.36% | 1.86% | 0.97% | -0.99% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2026-05-31 | $53.86M | - |
| 2025-05-31 | $55.89M | - |
| 2024-05-31 | $76.06M | - |
| 2023-05-31 | $44.62M | $49.82M |
| 2022-05-31 | $28.82M | $25.00M |
| 2021-05-31 | $48.16M | - |
| 2020-05-31 | $54.44M | - |
| 2019-05-31 | $227.64M | $124.41M |
| 2018-05-31 | $74.10M | $86.62M |
| 2017-05-31 | $47.54M | $91.32M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2026-05-31 | $508.00K | $13.96M |
| 2025-05-31 | $-14.59M | $9.77M |
| 2024-05-31 | $-30.68M | $10.53M |
| 2023-05-31 | $-3.73M | $11.16M |
| 2022-05-31 | $-11.49M | $10.69M |
| 2021-05-31 | $18.91M | $8.63M |
| 2020-05-31 | $-21.79M | $7.59M |
| 2019-05-31 | $34.32M | $9.25M |
| 2018-05-31 | $38.90M | $7.91M |
| 2017-05-31 | $52.74M | $6.18M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-01
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-14 | May/2026 | - |
| 2026-04-02 | - | - |
| 2026-01-06 | - | - |
| 2025-10-02 | - | - |
| 2025-07-15 | - | - |
| 2025-04-02 | - | - |
| 2025-01-08 | - | - |
| 2025-01-03 | - | - |
Filings and sources
- Company website
- angiodynamics.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades